Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120
- PMID: 9795384
- DOI: 10.1016/s0264-410x(98)00182-0
Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120
Abstract
Although it is known that some human immune sera possess potent neutralizing activities for primary viruses, the identity of the target epitopes mediating this neutralization is unknown, and currently available immunogens have not been able to induce such activities. Using recombinant fusion glycoproteins expressing native V1/V2 domains of gp120 we have found that sera from a subset of HIV-1-infected humans contain antibodies that recognize broadly conserved V1/V2 epitopes. Such antibodies were isolated from one human serum by affinity chromatography on a column containing a V1/V2 fusion protein, and shown to efficiently neutralize several macrophage-tropic HIV-1 isolates. Rodents immunized with the purified V1/V2 fusion protein produced antibodies reactive with unrelated V1/V2 fusion proteins and with heterologous gp120s. V1/V2-specific immunoglobulins isolated from sera of these animals by affinity chromatography also possessed potent neutralization activity for several primary HIV-1 isolates. These results indicate that the V1/V2 domain of HIV-1 gp120 contains conserved epitopes that mediate potent neutralization of primary viruses, and suggest that subunit vaccines that efficiently induce such antibodies may provide protective humoral immunity against clinically relevant HIV-1 isolates.
Similar articles
-
Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains.J Virol. 1994 Jan;68(1):400-10. doi: 10.1128/JVI.68.1.400-410.1994. J Virol. 1994. PMID: 7504740 Free PMC article.
-
Neutralization epitopes of the HIV-1 primary isolate DH012.Vaccine. 2003 Jul 4;21(23):3301-6. doi: 10.1016/s0264-410x(03)00218-4. Vaccine. 2003. PMID: 12804861
-
The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.J Virol. 2004 May;78(10):5205-15. doi: 10.1128/jvi.78.10.5205-5215.2004. J Virol. 2004. PMID: 15113902 Free PMC article.
-
[Role of the HIV-1 gp120 V1/V2 domains in the induction of neutralizing antibodies].Enferm Infecc Microbiol Clin. 2009 Nov;27(9):523-30. doi: 10.1016/j.eimc.2008.02.010. Epub 2009 May 1. Enferm Infecc Microbiol Clin. 2009. PMID: 19409660 Review. Spanish.
-
Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors.Curr Opin HIV AIDS. 2009 Mar;4(2):112-7. doi: 10.1097/COH.0b013e328322f95e. Curr Opin HIV AIDS. 2009. PMID: 19339949 Free PMC article. Review.
Cited by
-
IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens.AIDS Res Hum Retroviruses. 2015 Nov;31(11):1178-86. doi: 10.1089/AID.2015.0034. Epub 2015 Sep 9. AIDS Res Hum Retroviruses. 2015. PMID: 26234467 Free PMC article. Clinical Trial.
-
Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost.J Infect Dis. 2017 Nov 27;216(9):1080-1090. doi: 10.1093/infdis/jix456. J Infect Dis. 2017. PMID: 28968759 Free PMC article.
-
HIV-1 Env DNA prime plus gp120 and gp70-V1V2 boosts induce high level of V1V2-specific IgG and ADCC responses and low level of Env-specific IgA response: implication for improving RV144 vaccine regimen.Emerg Microbes Infect. 2017 Nov 29;6(11):e102. doi: 10.1038/emi.2017.90. Emerg Microbes Infect. 2017. PMID: 29184156 Free PMC article. No abstract available.
-
Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals.Virology. 2012 Jun 5;427(2):198-207. doi: 10.1016/j.virol.2012.02.003. Epub 2012 Mar 7. Virology. 2012. PMID: 22402248 Free PMC article.
-
Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses.Cell Rep. 2019 Jul 23;28(4):877-895.e6. doi: 10.1016/j.celrep.2019.06.074. Cell Rep. 2019. PMID: 31340151 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources